aTyr Pharma
ATYR
75 hedge funds and large institutions have $199M invested in aTyr Pharma in 2024 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 8 closing their positions.
275% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 8
163% more capital inflows, than outflows
Capital inflows: $38.5M | Capital outflows: $14.6M
92% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 12
39% more funds holding
Funds holding: 54 → 75 (+21)
2.21% more ownership
Funds ownership: 63.15% → 65.36% (+2.2%)
18% less call options, than puts
Call options by funds: $195K | Put options by funds: $237K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14.8M |
| 2 |
Octagon Capital Advisors
New York
|
+$2.73M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.2M |
| 4 |
Ally Bridge Group
New York
|
+$2.12M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Checkpoint Capital
San Francisco,
California
|
-$3.95M |
| 2 |
Logos Global Management
San Francisco,
California
|
-$3.03M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.89M |
| 4 |
Renaissance Technologies
New York
|
-$1.74M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.36M |
ATYR Hedge Fund Activity: Q4 2024 in Review
75 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2024, worth a combined $199M — up 136% from $84.3M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ATYR positions and 8 closed out — a net gain of 22 holders — while 23 added to existing stakes and 12 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $14.8M. The largest seller was Checkpoint Capital, cutting an estimated $3.95M.
- 75 institutional investors held aTyr Pharma (ATYR) as of Q4 2024, up from 54 in Q3 2024.
- Funds reported $199M of aTyr Pharma stock for Q4 2024, up 136% quarter-over-quarter.
- 30 funds opened new aTyr Pharma positions in Q4 2024 and 8 closed out, a net change of +22 holders.
- The largest aTyr Pharma buyer in Q4 2024 was Point72 Asset Management, an estimated $14.8M added.
- The largest aTyr Pharma seller in Q4 2024 was Checkpoint Capital, an estimated $3.95M sold.
Based on aggregated 13F filings for Q4 2024.